Review of pharmacokinetics of levothyroxine, with specific focus on patient with thyroid carcinoma

Rajesh Kumar, Mukhyaprana Prabhu, Sreedhar R. Pai, Vasudev Shenoy

Research output: Contribution to journalReview article

Abstract

Total or near to Total thyroidectomy with Radio Iodine treatment is current therapy for Thyroid cancer. Post thyroidectomy the patients are on Levothyroxine as a supplement therapy to maintain the Thyroid hormone levels. Levothyroxine has been considered as a narrow therapeutic index drug. In Thyroid cancer patients, radio-iodine ablation procedure causes hypothyroid state which will be further elongated by the administration of sub optimal doses and hyperthyroid symptoms with higher doses. This article would evaluate the pharmacokinetics of levothyroxine and in specific focus in patients with papillary carcinoma followed with thyroidectomy with Radio iodine treatment. Materials and Methods: The references are review from published literature and web based information. Results: Levothyroxine is considered as a narrow therapeutic index drug and hence individualization of the dose in a particular patient is important for optimal therapeutic effect. Conclusion: Review of pharmacokinetics of levothyroxine in various disease condition, coexisting disease and concomitant medication suggested for optimization of the dose of levothyroxine for avoiding the toxic adverse effects due to hypothyroid or hyperthyroid conditions.

Original languageEnglish
JournalJournal of Global Pharma Technology
Volume9
Issue number10
Publication statusPublished - 01-01-2017

Fingerprint

Thyroxine
Thyroid Neoplasms
Pharmacokinetics
Thyroidectomy
Radio
Iodine
Hyperthyroidism
Therapeutics
Poisons
Papillary Carcinoma
Therapeutic Uses
Thyroid Hormones
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{3d3c649bce88486c8af137abc4f964e7,
title = "Review of pharmacokinetics of levothyroxine, with specific focus on patient with thyroid carcinoma",
abstract = "Total or near to Total thyroidectomy with Radio Iodine treatment is current therapy for Thyroid cancer. Post thyroidectomy the patients are on Levothyroxine as a supplement therapy to maintain the Thyroid hormone levels. Levothyroxine has been considered as a narrow therapeutic index drug. In Thyroid cancer patients, radio-iodine ablation procedure causes hypothyroid state which will be further elongated by the administration of sub optimal doses and hyperthyroid symptoms with higher doses. This article would evaluate the pharmacokinetics of levothyroxine and in specific focus in patients with papillary carcinoma followed with thyroidectomy with Radio iodine treatment. Materials and Methods: The references are review from published literature and web based information. Results: Levothyroxine is considered as a narrow therapeutic index drug and hence individualization of the dose in a particular patient is important for optimal therapeutic effect. Conclusion: Review of pharmacokinetics of levothyroxine in various disease condition, coexisting disease and concomitant medication suggested for optimization of the dose of levothyroxine for avoiding the toxic adverse effects due to hypothyroid or hyperthyroid conditions.",
author = "Rajesh Kumar and Mukhyaprana Prabhu and Pai, {Sreedhar R.} and Vasudev Shenoy",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "9",
journal = "Journal of Global Pharma Technology",
issn = "0975-8542",
publisher = "Journal of Global Pharma Technology",
number = "10",

}

Review of pharmacokinetics of levothyroxine, with specific focus on patient with thyroid carcinoma. / Kumar, Rajesh; Prabhu, Mukhyaprana; Pai, Sreedhar R.; Shenoy, Vasudev.

In: Journal of Global Pharma Technology, Vol. 9, No. 10, 01.01.2017.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Review of pharmacokinetics of levothyroxine, with specific focus on patient with thyroid carcinoma

AU - Kumar, Rajesh

AU - Prabhu, Mukhyaprana

AU - Pai, Sreedhar R.

AU - Shenoy, Vasudev

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Total or near to Total thyroidectomy with Radio Iodine treatment is current therapy for Thyroid cancer. Post thyroidectomy the patients are on Levothyroxine as a supplement therapy to maintain the Thyroid hormone levels. Levothyroxine has been considered as a narrow therapeutic index drug. In Thyroid cancer patients, radio-iodine ablation procedure causes hypothyroid state which will be further elongated by the administration of sub optimal doses and hyperthyroid symptoms with higher doses. This article would evaluate the pharmacokinetics of levothyroxine and in specific focus in patients with papillary carcinoma followed with thyroidectomy with Radio iodine treatment. Materials and Methods: The references are review from published literature and web based information. Results: Levothyroxine is considered as a narrow therapeutic index drug and hence individualization of the dose in a particular patient is important for optimal therapeutic effect. Conclusion: Review of pharmacokinetics of levothyroxine in various disease condition, coexisting disease and concomitant medication suggested for optimization of the dose of levothyroxine for avoiding the toxic adverse effects due to hypothyroid or hyperthyroid conditions.

AB - Total or near to Total thyroidectomy with Radio Iodine treatment is current therapy for Thyroid cancer. Post thyroidectomy the patients are on Levothyroxine as a supplement therapy to maintain the Thyroid hormone levels. Levothyroxine has been considered as a narrow therapeutic index drug. In Thyroid cancer patients, radio-iodine ablation procedure causes hypothyroid state which will be further elongated by the administration of sub optimal doses and hyperthyroid symptoms with higher doses. This article would evaluate the pharmacokinetics of levothyroxine and in specific focus in patients with papillary carcinoma followed with thyroidectomy with Radio iodine treatment. Materials and Methods: The references are review from published literature and web based information. Results: Levothyroxine is considered as a narrow therapeutic index drug and hence individualization of the dose in a particular patient is important for optimal therapeutic effect. Conclusion: Review of pharmacokinetics of levothyroxine in various disease condition, coexisting disease and concomitant medication suggested for optimization of the dose of levothyroxine for avoiding the toxic adverse effects due to hypothyroid or hyperthyroid conditions.

UR - http://www.scopus.com/inward/record.url?scp=85066870059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066870059&partnerID=8YFLogxK

M3 - Review article

VL - 9

JO - Journal of Global Pharma Technology

JF - Journal of Global Pharma Technology

SN - 0975-8542

IS - 10

ER -